CPC A61K 35/28 (2013.01) [A61K 48/005 (2013.01); A61P 3/10 (2018.01); C07K 14/525 (2013.01); G01N 33/68 (2013.01); A61K 38/00 (2013.01); G01N 2333/82 (2013.01)] | 17 Claims |
1. A method for treating complications related to acute or chronic hyperglycemia, the method comprising, in a patient presenting with one or more of said complications selected from diabetes mellitus, insulin resistance, hepatic steatosis, non-alcoholic hepatic steatosis, fibrotic liver disease, vascular disease, or intestinal inflammation:
determining a level of lipocalin-2 (LCN2) in a patient; and
if the level of LCN2 is greater than a predetermined-value, then
administering to the patient a therapeutically effective amount of a selective inhibitor of soluble tumor necrosis factor alpha (solTNF-α), the selective inhibitor of solTNF-a being selected as one which inhibits solTNF-α without inhibiting transmembrane TNF-α, wherein the selective inhibitor of solTNF-a comprises: a dominant negative tumor necrosis factor (DN-TNF)-α protein, a nucleic acid encoding the DN-TNF-α protein, or a combination thereof,
whereby said complications are treated.
|